Liver Disease; Cholesterol; Personalized Medicine; Alternative Medicine; Diseases and Conditions; Gene Therapy; Chronic Illness; Genes

CRISPR Gene-Editing Therapy Slashes LDL Cholesterol and Triglycerides

by

A single infusion of the experimental CRISPR-Cas9 gene-editing therapy CTX310 successfully cut low-density lipoprotein (“bad”) cholesterol by 52.5% and triglycerides by 47.8% after twelve months in a Phase 1 clinical … Read More